MDT Stock - Medtronic plc
Unlock GoAI Insights for MDT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $33.54B | $32.36B | $31.23B | $31.69B | $30.12B |
| Gross Profit | $21.91B | $21.15B | $20.51B | $21.54B | $19.63B |
| Gross Margin | 65.3% | 65.3% | 65.7% | 68.0% | 65.2% |
| Operating Income | $5.96B | $5.14B | $5.49B | $5.75B | $4.48B |
| Net Income | $4.66B | $3.68B | $3.76B | $5.04B | $3.61B |
| Net Margin | 13.9% | 11.4% | 12.0% | 15.9% | 12.0% |
| EPS | $3.63 | $2.77 | $2.83 | $3.75 | $2.68 |
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 19th 2025 | Goldman | Upgrade | Neutral | $111 |
| June 30th 2025 | Wolfe Research | Upgrade | Peer Perform | - |
| June 16th 2025 | Leerink Partners | Initiation | Outperform | $110 |
| March 4th 2025 | Citigroup | Upgrade | Buy | $107← $92 |
| October 10th 2024 | RBC Capital Mkts | Upgrade | Outperform | $105← $98 |
| August 21st 2024 | Oppenheimer | Reiterated | Perform | $94← $92 |
| August 15th 2024 | UBS | Upgrade | Neutral | $90← $76 |
| August 14th 2024 | Stifel | Downgrade | Hold | $85← $100 |
| May 30th 2024 | Goldman | Initiation | Sell | $83 |
| July 19th 2023 | Robert W. Baird | Initiation | Neutral | $90 |
| June 30th 2023 | CL King | Initiation | Buy | $106 |
| May 30th 2023 | Morgan Stanley | Upgrade | Overweight | $104 |
| April 24th 2023 | Wells Fargo | Upgrade | Overweight | $100← $77 |
| March 29th 2023 | UBS | Downgrade | Sell | $79← $127 |
| January 9th 2023 | RBC Capital Mkts | Downgrade | Sector Perform | $89← $102 |
Earnings History & Surprises
MDTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 20, 2026 | — | — | — | — |
Q1 2026 | Feb 17, 2026 | $1.34 | — | — | — |
Q4 2025 | Nov 18, 2025 | $1.31 | $1.36 | +3.8% | ✓ BEAT |
Q3 2025 | Aug 19, 2025 | $1.23 | $1.26 | +2.4% | ✓ BEAT |
Q2 2025 | May 21, 2025 | $1.58 | $1.62 | +2.5% | ✓ BEAT |
Q1 2025 | Feb 18, 2025 | $1.36 | $1.39 | +2.2% | ✓ BEAT |
Q4 2024 | Nov 19, 2024 | $1.25 | $1.26 | +0.8% | ✓ BEAT |
Q3 2024 | Aug 20, 2024 | $1.20 | $1.23 | +2.5% | ✓ BEAT |
Q2 2024 | May 23, 2024 | $1.45 | $1.46 | +0.7% | ✓ BEAT |
Q1 2024 | Feb 20, 2024 | $1.26 | $1.30 | +3.2% | ✓ BEAT |
Q4 2023 | Nov 21, 2023 | $1.18 | $1.25 | +5.9% | ✓ BEAT |
Q3 2023 | Aug 22, 2023 | $1.11 | $1.20 | +8.1% | ✓ BEAT |
Q2 2023 | May 25, 2023 | $1.56 | $1.57 | +0.6% | ✓ BEAT |
Q1 2023 | Feb 21, 2023 | $1.26 | $1.30 | +3.2% | ✓ BEAT |
Q4 2022 | Nov 22, 2022 | $1.28 | $1.30 | +1.6% | ✓ BEAT |
Q3 2022 | Aug 23, 2022 | $1.12 | $1.13 | +0.9% | ✓ BEAT |
Q2 2022 | May 26, 2022 | $1.56 | $1.52 | -2.6% | ✗ MISS |
Q1 2022 | Feb 22, 2022 | $1.36 | $1.37 | +0.7% | ✓ BEAT |
Q4 2021 | Nov 23, 2021 | $1.29 | $1.32 | +2.3% | ✓ BEAT |
Q3 2021 | Aug 24, 2021 | $1.32 | $1.41 | +6.8% | ✓ BEAT |
Latest News
Trump Administration Proposes Rule Banning Medicaid And CHIP From Paying For Gender Affirming Care
➖ NeutralTruist Securities Maintains Hold on Medtronic, Lowers Price Target to $107
➖ NeutralOrchestra BioMed Highlights Strategic Collaboration With Medtronic And Progress Of AVIM Therapy And Virtue SAB At 2025 ICI Meeting
📈 PositiveMedtronic Receives FDA Clearance For Hugo RAS System For Use In Urologic Surgical Procedures
📈 PositiveMedtronic Commercially Launches MiniMed 780G System In U.S.
📈 PositiveBarclays Maintains Overweight on Medtronic, Raises Price Target to $111
📈 PositiveTruist Securities Maintains Hold on Medtronic, Raises Price Target to $110
➖ NeutralMorgan Stanley Maintains Overweight on Medtronic, Raises Price Target to $117
📈 PositiveRBC Capital Maintains Outperform on Medtronic, Raises Price Target to $118
📈 PositiveUBS Maintains Neutral on Medtronic, Raises Price Target to $102
➖ NeutralWells Fargo Maintains Overweight on Medtronic, Raises Price Target to $114
📈 PositiveBaird Maintains Neutral on Medtronic, Raises Price Target to $109
➖ NeutralGoldman Sachs Upgrades Medtronic to Neutral, Raises Price Target to $111
➖ NeutralMedtronic Exec Says Bigger Portion Of Tariff Hit In Q3, Then Will Have Carryover Into Fiscal 2027
📉 NegativeMedtronic shares are trading higher after the company reported better-than-expected Q2 financial results and raised FY26 guidance.
📈 PositiveMedtronic CEO Says Co Now Sees FX Tailwind For Fiscal 2026 Revenue Of $625M-$725M
📈 PositiveMedtronic Raises FY2026 Adj EPS Guidance from $5.60-$5.66 to $5.62-$5.66 vs $5.63 Est
📈 PositiveMedtronic Q2 2026 Adj. EPS $1.36 Beats $1.31 Estimate, Sales $8.961B Beat $8.865B Estimate
📈 PositiveJP Morgan Maintains Neutral on Medtronic, Raises Price Target to $100
➖ NeutralTruist Securities Maintains Hold on Medtronic, Raises Price Target to $103
➖ NeutralFrequently Asked Questions about MDT
What is MDT's current stock price?
What is the analyst price target for MDT?
What sector is Medtronic plc in?
What is MDT's market cap?
Does MDT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MDT for comparison